PANG
vs
D
DAX Index
PANG
Over the past 12 months, PANG has underperformed DAX Index, delivering a return of -5% compared to the DAX Index's +19% growth.
Stocks Performance
PANG vs DAX Index
Performance Gap
PANG vs DAX Index
Performance By Year
PANG vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pangaea Oncology SA
Glance View
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.